<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36210445</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Pathophysiology of Post-COVID syndromes: a new perspective.</ArticleTitle><Pagination><StartPage>158</StartPage><MedlinePgn>158</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">158</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-022-01891-2</ELocationID><Abstract><AbstractText>Most COVID-19 patients recovered with low mortality; however, some patients experienced long-term symptoms described as "long-COVID" or "Post-COVID syndrome" (PCS). Patients may have persisting symptoms for weeks after acute SARS-CoV-2 infection, including dyspnea, fatigue, myalgia, insomnia, cognitive and olfactory disorders. These symptoms may last for months in some patients. PCS may progress in association with the development of mast cell activation syndrome (MCAS), which is a distinct kind of mast cell activation disorder, characterized by hyper-activation of mast cells with inappropriate and excessive release of chemical mediators. COVID-19 survivors, mainly women, and patients with persistent severe fatigue for 10&#xa0;weeks after recovery with a history of neuropsychiatric disorders are more prone to develop PCS. High D-dimer levels and blood urea nitrogen were observed to be risk factors associated with pulmonary dysfunction in COVID-19 survivors 3&#xa0;months post-hospital discharge with the development of PCS. PCS has systemic manifestations that resolve with time with no further complications. However, the final outcomes of PCS are chiefly unknown. Persistence of inflammatory reactions, autoimmune mimicry, and reactivation of pathogens together with host microbiome alterations may contribute to the development of PCS. The deregulated release of inflammatory mediators in MCAS produces extraordinary symptoms in patients with PCS. The development of MCAS during the course of SARS-CoV-2 infection is correlated to COVID-19 severity and the development of PCS. Therefore, MCAS is treated by antihistamines, inhibition of synthesis of mediators, inhibition of mediator release, and inhibition of degranulation of mast cells.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Batiha</LastName><ForeName>Gaber El-Saber</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Al Beheira, 22511, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Kuraishy</LastName><ForeName>Hayder M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, Baghdad, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Gareeb</LastName><ForeName>Ali I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, Baghdad, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welson</LastName><ForeName>Nermeen N</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Beni-Suef University, Beni Suef, 62511, Egypt. nermeennemr@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006633">Histamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006633" MajorTopicYN="N">Histamine Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008415" MajorTopicYN="Y">Mastocytosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Mast cell activation syndrome</Keyword><Keyword MajorTopicYN="N">Pathogenesis</Keyword><Keyword MajorTopicYN="N">Post-COVID syndrome</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>9</Day><Hour>23</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36210445</ArticleId><ArticleId IdType="pmc">PMC9548310</ArticleId><ArticleId IdType="doi">10.1186/s12985-022-01891-2</ArticleId><ArticleId IdType="pii">10.1186/s12985-022-01891-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI. From SARS-CoV to nCoV-2019: ruction and argument. Arch Clin Infect Dis. 2020;15(2):e102624.</Citation></Reference><Reference><Citation>Moubarak M, Kasozi KI, Hetta HF, Shaheen HM, Rauf A, Al-Kuraishy HM, et al. The rise of SARS-CoV-2 variants and the role of convalescent plasma therapy for management of infections. Life. 2021;11(8):734. doi: 10.3390/life11080734.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11080734</ArticleId><ArticleId IdType="pmc">PMC8399171</ArticleId><ArticleId IdType="pubmed">34440478</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhayyat SS, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, AboKamer AM, Batiha GE, Simal-Gandara J. Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail. Inflamm Res. 2022;8:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9360649</ArticleId><ArticleId IdType="pubmed">35941297</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Almulaiky YQ, Cruz-Martins N, Batiha GE. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of COVID-19: the enigmatic entity. Eur J Pharmacol. 2021;5(904):174196. doi: 10.1016/j.ejphar.2021.174196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174196</ArticleId><ArticleId IdType="pmc">PMC8123523</ArticleId><ArticleId IdType="pubmed">34004207</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Batiha GE, Faidah H, Al-Gareeb AI, Saad HM, Simal-Gandara J. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology. 2022;31:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9430017</ArticleId><ArticleId IdType="pubmed">36044102</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Alblihed M, Cruz-Martins N, Batiha GE. COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type ii diabetes mellitus: the anti-inflammatory role of metformin. Front Med. 2021;19(8):110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944640</ArticleId><ArticleId IdType="pubmed">33718411</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Alkazmi L, Habotta OA, Batiha GE. High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons. Inflammopharmacology. 2022;26:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9040700</ArticleId><ArticleId IdType="pubmed">35471628</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Hussien NR, Al-Naimi MS, Al-Buhadily AK, Al-Gareeb AI, Lungnier C. Renin-Angiotensin system and fibrinolytic pathway in COVID-19: one-way skepticism. Biomed Biotechnol Res J (BBRJ) 2020;4(5):33.</Citation></Reference><Reference><Citation>Mostafa-Hedeab G, Al-Kuraishy HM, Al-Gareeb AI, Welson NN, Batiha GE, Conte-Junior CA. Selinexor and COVID-19: the neglected warden. Front Pharmacol. 2022;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9086449</ArticleId><ArticleId IdType="pubmed">35559257</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Faidah H, Al-Maiahy TJ, Cruz-Martins N, Batiha GE. The looming effects of estrogen in COVID-19: a rocky rollout. Front Nutr. 2021;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012689</ArticleId><ArticleId IdType="pubmed">33816542</ArticleId></ArticleIdList></Reference><Reference><Citation>Babalghith AO, Al-kuraishy HM, Al-Gareeb AI, De Waard M, Sabatier JM, Saad HM, Batiha GE. The potential role of growth differentiation factor 15 in COVID-19: a corollary subjective effect or not? Diagnostics. 2022;12(9):2051. doi: 10.3390/diagnostics12092051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12092051</ArticleId><ArticleId IdType="pmc">PMC9497461</ArticleId><ArticleId IdType="pubmed">36140453</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Qusti S, Alshammari EM, Gyebi GA, Batiha GE. COVID-19-induced dysautonomia: a menace of sympathetic storm. ASN Neuro. 2021;13:17590914211057635. doi: 10.1177/17590914211057635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17590914211057635</ArticleId><ArticleId IdType="pmc">PMC8586167</ArticleId><ArticleId IdType="pubmed">34755562</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Butnariu M, Batiha GE. The crucial role of prolactin-lactogenic hormone in Covid-19. Mol Cell Biochem. 2022;11:1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8831165</ArticleId><ArticleId IdType="pubmed">35147901</ArticleId></ArticleIdList></Reference><Reference><Citation>McCorkell L, Assaf GS, Davis HE, Wei H, Akrami A. Patient-led research collaborative: embedding patients in the long COVID narrative. Pain Rep. 2021;6(1):e913. doi: 10.1097/PR9.0000000000000913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PR9.0000000000000913</ArticleId><ArticleId IdType="pmc">PMC8112577</ArticleId><ArticleId IdType="pubmed">33987484</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Aljowaie RM, Almutairi SM, Alexiou A, Batiha GE. The prospective effect of allopurinol on the oxidative stress index and endothelial dysfunction in covid-19. Inflammation. 2022;24:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865950</ArticleId><ArticleId IdType="pubmed">35199285</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicpinigaitis PV, Canning BJ. Is there (will there be) a post-COVID-19 chronic cough? Lung. 2020;198(6):863&#x2013;865. doi: 10.1007/s00408-020-00406-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-020-00406-6</ArticleId><ArticleId IdType="pmc">PMC7665087</ArticleId><ArticleId IdType="pubmed">33188436</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Welson NN, Batiha GE. Trimetazidine and COVID-19-induced acute cardiac injury: a missed key. Int J Clin Pharm. 2022;21:1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9022894</ArticleId><ArticleId IdType="pubmed">35449348</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;1(100):327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099&#x2013;1104. doi: 10.1016/j.jaci.2010.08.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2010.08.035</ArticleId><ArticleId IdType="pmc">PMC3753019</ArticleId><ArticleId IdType="pubmed">21035176</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349&#x2013;355. doi: 10.1016/j.jaci.2017.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2017.06.007</ArticleId><ArticleId IdType="pubmed">28780942</ArticleId></ArticleIdList></Reference><Reference><Citation>Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract. 2019;7(4):1097&#x2013;106. doi: 10.1016/j.jaip.2019.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2019.02.002</ArticleId><ArticleId IdType="pubmed">30961835</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court M, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Onohuean H, El-Saber BG. COVID-19 and erythrocrine function: the roller coaster and danger. Int J Immunopathol Pharmacol. 2022;14(36):03946320221103151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9124636</ArticleId><ArticleId IdType="pubmed">35590466</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, Sonbol FI, Batiha GE. Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties. Clin Exp Med. 2022;24:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9128329</ArticleId><ArticleId IdType="pubmed">35608715</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251&#x2013;2252. doi: 10.1001/jama.2020.22717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22717</ArticleId><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Amenta EM, et al. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7(12):ofaa509. doi: 10.1093/ofid/ofaa509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa509</ArticleId><ArticleId IdType="pmc">PMC7665635</ArticleId><ArticleId IdType="pubmed">33403218</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Fageyinbo MS, Batiha GE. Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19. Future Science OA. 2022 Mar(0):FSO797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017700</ArticleId><ArticleId IdType="pubmed">35662743</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, et al. Managing the long-term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID&#x2019;. Lancet Respir Med. 2021;9(2):129. doi: 10.1016/S2213-2600(21)00031-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Palacios-Ce&#xf1;a D, G&#xf3;mez-Mayordomo V, Cuadrado ML, Florencio LL. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J Environ Res Public Health. 2021;18(5):2621. doi: 10.3390/ijerph18052621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18052621</ArticleId><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung. 2021;199(2):113&#x2013;119. doi: 10.1007/s00408-021-00423-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-021-00423-z</ArticleId><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, et al. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification&#x2019;. Int J Environ Res Public Health. 2021;18(5):2621. doi: 10.3390/ijerph18052621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18052621</ArticleId><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr. 2021;15(3):869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelson M, Nel J, Blumberg L, et al. Long-COVID: An evolving problem with an extensive impact. S Afr Med J. 2020;111(1):10&#x2013;12. doi: 10.7196/SAMJ.2020.v111i11.15433.</Citation><ArticleIdList><ArticleId IdType="doi">10.7196/SAMJ.2020.v111i11.15433</ArticleId><ArticleId IdType="pubmed">33403997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Taylor S. NICE guideline on long COVID. BMJ. 2020;371:m4938. doi: 10.1136/bmj.m4938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4938</ArticleId><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Davido B, et al. Post-COVID-19 chronic symptoms: a postinfectious entity? Clin Microbiol Infect. 2020;26(11):1448&#x2013;1449. doi: 10.1016/j.cmi.2020.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.028</ArticleId><ArticleId IdType="pmc">PMC7376333</ArticleId><ArticleId IdType="pubmed">32712242</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A. Long-haul COVID. Neurology. 2020;95(13):559&#x2013;560. doi: 10.1212/WNL.0000000000010640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010640</ArticleId><ArticleId IdType="pubmed">32788251</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando HM, Bennett TD, Byrd JB, et al. Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information. medRxiv. 2021;383:590. doi: 10.1101/2021.03.20.21253896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.20.21253896</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dowds J, O&#x2019;Brien K, et al. Persistent poor health post-COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc. 2021 doi: 10.1513/AnnalsATS.202009-1175OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202009-1175OC</ArticleId><ArticleId IdType="pmc">PMC8456724</ArticleId><ArticleId IdType="pubmed">33413026</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Saber Batiha G, Al-Gareeb AI, Saad HM, Al-Kuraishy HM. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022;13:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9106274</ArticleId><ArticleId IdType="pubmed">35562628</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Espuny Pujol F, Munblit D, et al. Clinical characteristics, activity levels and mental health problems in children with Long COVID: a survey of 510 children. Preprints. 2021. 10.20944/preprints202103.0271.v1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9248023</ArticleId><ArticleId IdType="pubmed">35360923</ArticleId></ArticleIdList></Reference><Reference><Citation>Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease: a systematic review of the current data. Frontiers in medicine. 2021;8:392. doi: 10.3389/fmed.2021.653516.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.653516</ArticleId><ArticleId IdType="pmc">PMC8129035</ArticleId><ArticleId IdType="pubmed">34017846</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE. COVID-19 and L-arginine Supplementations: yet to find the missed key. Curr Protein Pept Sci. 2022;23(3):166&#x2013;169. doi: 10.2174/1389203723666220512104039.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203723666220512104039</ArticleId><ArticleId IdType="pubmed">35549865</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao FC, Guo KJ, Li ZR. Osteonecrosis of the femoral head in SARS patients: seven years later. Eur J Orthop Surg Traumatol. 2013;23(6):671&#x2013;677. doi: 10.1007/s00590-012-1054-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-012-1054-4</ArticleId><ArticleId IdType="pubmed">23412187</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLOS ONE. 2020;15(11):e0240784. doi: 10.1371/journal.pone.0240784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh IM, Saddik B, AlSwaidan N, AlAnazi A, Ramakrishnan RK, Alhazmi D, Aloufi A, AlSumait F, Berbari E, Halwani R. prevalence and predictors of post-acute COVID-19 syndrome (PACS) after hospital discharge: a cohort study with 4 months median follow-up. PLOS ONE. 2021;16(12):e0260568. doi: 10.1371/journal.pone.0260568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260568</ArticleId><ArticleId IdType="pmc">PMC8651136</ArticleId><ArticleId IdType="pubmed">34874962</ArticleId></ArticleIdList></Reference><Reference><Citation>Simani L, Ramezani M, Darazam IA, et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. J Neurovirol. 2021;27(1):154&#x2013;159. doi: 10.1007/s13365-021-00949-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00949-1</ArticleId><ArticleId IdType="pmc">PMC7852482</ArticleId><ArticleId IdType="pubmed">33528827</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Thomali AW, Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadiliy AK, De Waard M, Sabatier JM, Khan Khalil AA, Saad HM, Batiha GE. Role of Neuropilin 1 in COVID-19 Patients with Acute Ischemic Stroke. Biomedicines. 2022;10(8):2032. doi: 10.3390/biomedicines10082032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10082032</ArticleId><ArticleId IdType="pmc">PMC9405641</ArticleId><ArticleId IdType="pubmed">36009579</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavem K, Ghanima W, Olsen MK, et al. 1.5&#x2013;6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2021;76(4):405. doi: 10.1136/thoraxjnl-2020-216377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216377</ArticleId><ArticleId IdType="pmc">PMC7716295</ArticleId><ArticleId IdType="pubmed">33273028</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Mukerjee N, Al-Hamash SM, Al-Maiahy TJ, Batiha GE. 5-HT/CGRP pathway and Sumatriptan role in Covid-19. Biotechnol Genet Eng Rev. 2022;31:1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">36042570</ArticleId></ArticleIdList></Reference><Reference><Citation>Truffaut L, Demey L, Bruyneel AV, et al. Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission. Respir Res. 2021;22(1):29. doi: 10.1186/s12931-021-01625-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01625-y</ArticleId><ArticleId IdType="pmc">PMC7819622</ArticleId><ArticleId IdType="pubmed">33478527</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE. Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia. Curr Drug Targets. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35950254</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado J, Singh R, Collins T. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93(2):1013&#x2013;1022. doi: 10.1002/jmv.26368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawal G, Yadav S, Kumar R. Post-intensive care syndrome: an overview. J Transl Internal Med. 2017;5(2):90&#x2013;92. doi: 10.1515/jtim-2016-0016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jtim-2016-0016</ArticleId><ArticleId IdType="pmc">PMC5506407</ArticleId><ArticleId IdType="pubmed">28721340</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam H, Stucki G, Bickenbach J. COVID-19 and post intensive care syndrome: a call for action. J Rehabil Med. 2020;52:jrm00044. doi: 10.2340/16501977-2677.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/16501977-2677</ArticleId><ArticleId IdType="pubmed">32286675</ArticleId></ArticleIdList></Reference><Reference><Citation>Gameil MA, Marzouk RE, Elsebaie AH, Rozaik SE. Long-term clinical and biochemical residue after COVID-19 recovery. Egypt Liver J. 2021;11(1):1&#x2013;8. doi: 10.1186/s43066-021-00144-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43066-021-00144-1</ArticleId><ArticleId IdType="pmc">PMC8435147</ArticleId><ArticleId IdType="pubmed">34777873</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Al-Harcan NA, Alexiou A, Batiha GE. Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19. Endoc Metab Immune Disord Drug Targets. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35927893</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Liu Z, Tang L, Li L, Gan Q, Shi H, Jiao Q, Guan Y, Xie M, He X, Zhao H. Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. Int J Med Sci. 2021;18(1):29. doi: 10.7150/ijms.49728.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.49728</ArticleId><ArticleId IdType="pmc">PMC7738960</ArticleId><ArticleId IdType="pubmed">33390771</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, Okell T, Sheerin F, Xie C, Mahmod M, M&#xf3;zes FE. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;1(31):100683. doi: 10.1016/j.eclinm.2020.100683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100683</ArticleId><ArticleId IdType="pmc">PMC7808914</ArticleId><ArticleId IdType="pubmed">33490928</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, Ma WL, Wang X. Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med Sci. 2020; 35(47).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7721559</ArticleId><ArticleId IdType="pubmed">33289374</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudroff T, Fietsam AC, Deters JR, Bryant AD, Kamholz J. Post-COVID-19 fatigue: potential contributing factors. Brain Sci. 2020;10(12):1012. doi: 10.3390/brainsci10121012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10121012</ArticleId><ArticleId IdType="pmc">PMC7766297</ArticleId><ArticleId IdType="pubmed">33352638</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID GA, Post-Acute Care Study Group. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res. 2020;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7287410</ArticleId><ArticleId IdType="pubmed">32529595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020;17:1984&#x2013;1990. doi: 10.1016/j.hrthm.2020.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2020.06.026</ArticleId><ArticleId IdType="pmc">PMC7319645</ArticleId><ArticleId IdType="pubmed">32599178</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C, Laurent E, Lemaignen A, Lemaignen A, Beaufils E, Bourbao-Tournois C, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27:258&#x2013;263. doi: 10.1016/j.cmi.2020.09.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.052</ArticleId><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Alexiou A, Batiha GE. Calprotectin: the link between acute lung injury and gastrointestinal injury in Covid-19: Ban or boon. Curr Protein Peptide Sci. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35692161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52(6):575&#x2013;581. doi: 10.1016/j.arcmed.2021.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2021.03.010</ArticleId><ArticleId IdType="pmc">PMC8093949</ArticleId><ArticleId IdType="pubmed">33962805</ArticleId></ArticleIdList></Reference><Reference><Citation>Alemanno F, Houdayer E, Parma A, Spina A, Del Forno A, Scatolini A, et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: ACOVID-rehabilitation unit experience. PLOS ONE. 2021;16:e0246590. doi: 10.1371/journal.pone.0246590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246590</ArticleId><ArticleId IdType="pmc">PMC7870071</ArticleId><ArticleId IdType="pubmed">33556127</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE. Targeting and modulation of the natriuretic peptide system in Covid-19: a single or double-edged effect?. Curr Protein Peptide Sci. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35762551</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanbehzadeh S, Tavahomi M, Zanjari N, Ebrahimi-Takamjani I, Amiri-Arimi S. Physical and mental health complications post-COVID-19: scoping review. J Psychosom Res. 2021;1(147):110525. doi: 10.1016/j.jpsychores.2021.110525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2021.110525</ArticleId><ArticleId IdType="pmc">PMC8133797</ArticleId><ArticleId IdType="pubmed">34051516</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC, Park D. Incidence of post-traumatic stress disorder after coronavirus disease. Health Care. 2020;8:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712968</ArticleId><ArticleId IdType="pubmed">33008081</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Al-Hamash SM, Cavalu S, El-Bouseary MM, Sonbol FI, Batiha GE. Changes in the blood viscosity in patients with SARS-CoV-2 infection. Front Med. 2022;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9247235</ArticleId><ArticleId IdType="pubmed">35783600</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoppettuolo P, Borrelli S, Naeije G. Neurological involvement in SARS-CoV-2 infection: a clinical systematic review. Brain Behav Immun Health. 2020;5:100094. doi: 10.1016/j.bbih.2020.100094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2020.100094</ArticleId><ArticleId IdType="pmc">PMC7832728</ArticleId><ArticleId IdType="pubmed">33521692</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O, Merino E, Leon-Ramirez JM, Prunier L, Cavelier G, Thill MP, et al. COVID19-ALC research post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J. Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe5;hlberg M, Reistam U, Fedorowski A, Villacorta H, Horiuchi Y, Bax J, Pitt B, Matskeplishvili S, L&#xfc;scher TF, Weichert I, Thani KB. Post-COVID-19 tachycardia syndrome: a distinct phenotype of post-acute COVID-19 syndrome. Am J Med. 2021;134:1451&#x2013;1456. doi: 10.1016/j.amjmed.2021.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2021.07.004</ArticleId><ArticleId IdType="pmc">PMC8356730</ArticleId><ArticleId IdType="pubmed">34390682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862&#x2013;874. doi: 10.1038/nri3552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3552</ArticleId><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of inflammation: what controls its onset? Front Immunol. 2016;7:160. doi: 10.3389/fimmu.2016.00160.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00160</ArticleId><ArticleId IdType="pmc">PMC4845539</ArticleId><ArticleId IdType="pubmed">27199985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ca&#xf1;as CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020;1(145):110345. doi: 10.1016/j.mehy.2020.110345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110345</ArticleId><ArticleId IdType="pmc">PMC7556280</ArticleId><ArticleId IdType="pubmed">33080459</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton AH, Muenzer JT, Rasche D, et al. Reactivation of multiple viruses in patients with sepsis. PLOS ONE. 2014;9(2):e98819. doi: 10.1371/journal.pone.0098819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098819</ArticleId><ArticleId IdType="pmc">PMC4053360</ArticleId><ArticleId IdType="pubmed">24919177</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Zheng L, Li Z, Hao S, Ye F, Chen J, Gans HA, Yao X, Liao J, Wang S, Zeng M. Kinetics of SARS-CoV-2 positivity of infected and recovered patients from a single center. Sci Rep. 2020;10(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596704</ArticleId><ArticleId IdType="pubmed">33122706</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Negm WA, Alexiou A, Batiha GE. Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective. Inflammopharmacology. 2022;3:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362167</ArticleId><ArticleId IdType="pubmed">35922738</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, Van Hemelrijck M. Associations between immune-suppressive and stimulating drugs and novel COVID-19&#x2014;a systematic review of current evidence. ecancermedicalscience. 2020;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105343</ArticleId><ArticleId IdType="pubmed">32256705</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivashanmugam K, Kandasamy M, Subbiah R, Ravikumar V. Repurposing of histone deacetylase inhibitors: a promising strategy to combat pulmonary fibrosis promoted by TGF-&#x3b2; signalling in COVID-19 survivors. Life Sci. 2021;1(266):118883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831549</ArticleId><ArticleId IdType="pubmed">33316266</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvacho I, Piesche M. RGD-binding integrins and TGF-&#x3b2; in SARS-CoV-2 infections&#x2013;novel targets to treat COVID-19 patients? Clin Transl Immunol. 2021;10(3):e1240. doi: 10.1002/cti2.1240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1240</ArticleId><ArticleId IdType="pmc">PMC7971943</ArticleId><ArticleId IdType="pubmed">33747508</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz YM, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FV, Houben-Wilke S, Burtin C, Posthuma R, Franssen FM, van Loon N. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542. doi: 10.1183/23120541.00542-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Gombar S, Chang M, Hogan CA, Zehnder J, Boyd S, Pinsky BA, Shah NH. Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19. J Clin Virol. 2020;1(129):104477. doi: 10.1016/j.jcv.2020.104477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104477</ArticleId><ArticleId IdType="pmc">PMC7260561</ArticleId><ArticleId IdType="pubmed">32505778</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, Kurihara Y, Shimizu H, Misaki T, Okabe N. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2021;27(2):387&#x2013;389. doi: 10.1016/j.jiac.2020.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC7836222</ArticleId><ArticleId IdType="pubmed">33328135</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, Guo Q, Sun X, Zhao D, Shen J, Zhang H. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502&#x2013;505. doi: 10.1038/s41591-020-0817-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0817-4</ArticleId><ArticleId IdType="pmc">PMC7095102</ArticleId><ArticleId IdType="pubmed">32284613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouo T, Chaisawangwong W. SARS-CoV-2 as a superantigen in multisystem inflammatory syndrome in children. J Clin Investig; 2021;131(10).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121522</ArticleId><ArticleId IdType="pubmed">33844652</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon&#xe9;-Paut I, Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open. 2020;6(2):e001333. doi: 10.1136/rmdopen-2020-001333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001333</ArticleId><ArticleId IdType="pmc">PMC7425186</ArticleId><ArticleId IdType="pubmed">32611651</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, Mullally WJ, Pilgrim DM. Multisystem involvement in post&#x2010;acute sequelae of COVID&#x2010;19 (PASC). Ann Neurol. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011495</ArticleId><ArticleId IdType="pubmed">34952975</ArticleId></ArticleIdList></Reference><Reference><Citation>Schofield JR. Persistent antiphospholipid antibodies, mast cell activation syndrome, postural orthostatic tachycardia syndrome and post-COVID syndrome: 1 year on. Eur J Case Rep Internal Med. 2021;8(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8046288</ArticleId><ArticleId IdType="pubmed">33869099</ArticleId></ArticleIdList></Reference><Reference><Citation>Assar S, Pournazari M, Soufivand P, Mohamadzadeh D. Systemic lupus erythematosus after coronavirus disease-2019 (COVID-19) infection: case-based review. Egypt Rheumatol. 2022;44(2):145&#x2013;149. doi: 10.1016/j.ejr.2021.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejr.2021.08.013</ArticleId><ArticleId IdType="pmc">PMC8511647</ArticleId><ArticleId IdType="pubmed">38620966</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese J, Sandmann S, Ochs K, Schrempf IM, Fr&#xf6;mmel C, Dugas M, Schmidt HH, Vollenberg R, Tepasse PR. Persistent symptoms and lab abnormalities in patients who recovered from COVID-19. Sci Rep. 2021;11(1):1&#x2013;8. doi: 10.1038/s41598-021-91270-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91270-8</ArticleId><ArticleId IdType="pmc">PMC8211641</ArticleId><ArticleId IdType="pubmed">34140539</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100463</ArticleId><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377(6):562&#x2013;572. doi: 10.1056/NEJMra1608077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1608077</ArticleId><ArticleId IdType="pubmed">28792873</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Borst B, et al. Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis. 2020; ciaa1750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717214</ArticleId><ArticleId IdType="pubmed">33220049</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Yang H, Lei P, et al. Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge. J Xray Sci Technol. 2020;28(3):383&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7369060</ArticleId><ArticleId IdType="pubmed">32474479</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Zhao X, Wang Y, et al. Damaged lung gas-exchange function of discharged COVID-19 patients detected by hyperpolarized (129)Xe MRI. Sci Adv. 2020;7(1):eabc8180. doi: 10.1126/sciadv.abc8180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc8180</ArticleId><ArticleId IdType="pmc">PMC7775756</ArticleId><ArticleId IdType="pubmed">33219111</ArticleId></ArticleIdList></Reference><Reference><Citation>Crameri GAG, Bielecki M, Z&#xfc;st R, et al. Reduced maximal aerobic capacity after COVID-19 in young adult recruits, Switzerland, May 2020. Euro Surveill. 2020;25(36):2001542. doi: 10.2807/1560-7917.ES.2020.25.36.2001542.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.36.2001542</ArticleId><ArticleId IdType="pmc">PMC7502899</ArticleId><ArticleId IdType="pubmed">32914744</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J. 2014;43(1):276&#x2013;285. doi: 10.1183/09031936.00196412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00196412</ArticleId><ArticleId IdType="pmc">PMC4015132</ArticleId><ArticleId IdType="pubmed">23520315</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai DK, Sharma P, Kumar R. Post COVID 19 pulmonary fibrosis Is it real threat? Indian J Tuberc. 2021;68(3):330&#x2013;333. doi: 10.1016/j.ijtb.2020.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijtb.2020.11.003</ArticleId><ArticleId IdType="pmc">PMC7654356</ArticleId><ArticleId IdType="pubmed">34099197</ArticleId></ArticleIdList></Reference><Reference><Citation>Herridge MS, Tansey CM, Matt&#xe9; A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293&#x2013;1304. doi: 10.1056/NEJMoa1011802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1011802</ArticleId><ArticleId IdType="pubmed">21470008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol. 2021;12(2574):136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Yu B, Yang Y, Huang J, Liang Y, Zhou J, Li L, Peng X, Cheng B, Lin Y. Immunological and inflammatory profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. Int Immunopharmacol. 2021;97:107685. doi: 10.1016/j.intimp.2021.107685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107685</ArticleId><ArticleId IdType="pmc">PMC8052478</ArticleId><ArticleId IdType="pubmed">33951560</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2020;76:399&#x2013;401. doi: 10.1136/thoraxjnl-2020-216086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, Antinori S. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis. 2020;71(15):889&#x2013;890. doi: 10.1093/cid/ciaa330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa330</ArticleId><ArticleId IdType="pmc">PMC7184514</ArticleId><ArticleId IdType="pubmed">32215618</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China JAMA Neurol. 2020;77(6):683&#x2013;690. doi: 10.1001/jamaneurol.2020.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Buhadily AK, Hussien NR, Al-Niemi MS, Al-Kuraishy HM, Al-Gareeb AI. Misfortune and spy story in the neurological manifestations of COVID-19. J Pak Med Assoc. 2021;1:S157&#x2013;S160.</Citation><ArticleIdList><ArticleId IdType="pubmed">35130240</ArticleId></ArticleIdList></Reference><Reference><Citation>Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurol Sci. 2020;41(7):1667&#x2013;1671. doi: 10.1007/s10072-020-04486-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04486-3</ArticleId><ArticleId IdType="pmc">PMC7262683</ArticleId><ArticleId IdType="pubmed">32483687</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Moloney D, Finucane C, McCarthy K, Bergin C, Bannan C, Kenny R-A. Fatigue following COVID-19 infection is not associated with autonomic dysfunction. PLOS ONE. 2021;16:e0247280. doi: 10.1371/journal.pone.0247280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247280</ArticleId><ArticleId IdType="pmc">PMC7906457</ArticleId><ArticleId IdType="pubmed">33630906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay A. A paradigm for post-COVID-19 fatigue syndrome analogous to ME/CFS. Front Neurol. 2021;12:1334. doi: 10.3389/fneur.2021.701419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.701419</ArticleId><ArticleId IdType="pmc">PMC8365156</ArticleId><ArticleId IdType="pubmed">34408721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryabkova VA, Churilov LP, Shoenfeld Y. Neuroimmunology: What role for autoimmunity, neuroinflammation, and small fiber neuropathy in fibromyalgia, chronic fatigue syndrome, and adverse events after human papillomavirus vaccination? Int J Mol Sci. 2019;20:5164. doi: 10.3390/ijms20205164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20205164</ArticleId><ArticleId IdType="pmc">PMC6834318</ArticleId><ArticleId IdType="pubmed">31635218</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med. 2021;18(7):1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang SW, Helmeste D, Leonard B. Inflammatory neuropsychiatric disorders and COVID-19 neuroinflammation. Acta Neuropsychiatr. 2021;33(4):165&#x2013;177. doi: 10.1017/neu.2021.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/neu.2021.13</ArticleId><ArticleId IdType="pubmed">33926589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EM, Furlan R, Ciceri F, Rovere-Querini P, Benedetti F. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun. 2020;1(89):594&#x2013;600. doi: 10.1016/j.bbi.2020.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.07.037</ArticleId><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC, Jia T, Zhao Y, Wang D, Xiao A, Yin B. Cerebral micro-structural changes in COVID-19 patients&#x2013;an MRI-based 3-month follow-up study. EClinicalMedicine. 2020;1(25):100484. doi: 10.1016/j.eclinm.2020.100484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100484</ArticleId><ArticleId IdType="pmc">PMC7396952</ArticleId><ArticleId IdType="pubmed">32838240</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, Jayaseelan DL, Kumar G, Raftopoulos RE, Zambreanu L, Vivekanandam V. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143(10):3104&#x2013;3120. doi: 10.1093/brain/awaa240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hanlon S, Inouye SK. Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing. 2020;49:497&#x2013;498. doi: 10.1093/ageing/afaa094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afaa094</ArticleId><ArticleId IdType="pmc">PMC7239228</ArticleId><ArticleId IdType="pubmed">32374367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariyanto TI, Putri C, Hananto JE, Arisa J, Situmeang RF, Kurniawan A. Delirium is a good predictor for poor outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review, meta-analysis, and meta-regression. J Psychiatr Res. 2021;1(142):361&#x2013;368. doi: 10.1016/j.jpsychires.2021.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2021.08.031</ArticleId><ArticleId IdType="pmc">PMC8376475</ArticleId><ArticleId IdType="pubmed">34425488</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611&#x2013;627. doi: 10.1016/S2215-0366(20)30203-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30203-0</ArticleId><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416&#x2013;427. doi: 10.1016/S2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulfamante G, Chiumello D, Canevini MP, Priori A, Mazzanti M, Centanni S, Felisati G. First ultrastructural autoptic findings of SARS-Cov-2 in olfactory pathways and brainstem.</Citation><ArticleIdList><ArticleId IdType="pubmed">32401000</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Persistent brainstem dysfunction in long-COVID: a hypothesis. ACS Chem Neurosci. 2021;12(4):573&#x2013;580. doi: 10.1021/acschemneuro.0c00793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00793</ArticleId><ArticleId IdType="pubmed">33538586</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, L&#xfc;tgehetmann M, Hagel C, Sperhake JP, Schr&#xf6;der AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M, Dottermusch M. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919&#x2013;929. doi: 10.1016/S1474-4422(20)30308-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, Adams G, Hornick JL, Padera RF, Jr, Sabeti P. Neuropathological features of COVID-19. N Engl J Med. 2020;383(10):989&#x2013;992. doi: 10.1056/NEJMc2019373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2019373</ArticleId><ArticleId IdType="pmc">PMC7304421</ArticleId><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Majolo F, Silva GL, Vieira L, Anli C, Timmers LF, Laufer S, Goettert MI. Neuropsychiatric disorders and COVID-19: what we know so far. Pharmaceuticals. 2021;14(9):933. doi: 10.3390/ph14090933.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14090933</ArticleId><ArticleId IdType="pmc">PMC8465079</ArticleId><ArticleId IdType="pubmed">34577633</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D, Jahan S, Khan A, Siddiqui AJ, Redhu NS, Khan J, Banwas S, Alshehri B, Alaidarous M. Neurological manifestation of SARS-CoV-2 induced inflammation and possible therapeutic strategies against COVID-19. Mol Neurobiol. 2021;58(7):3417&#x2013;3434. doi: 10.1007/s12035-021-02318-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02318-9</ArticleId><ArticleId IdType="pmc">PMC7955900</ArticleId><ArticleId IdType="pubmed">33715108</ArticleId></ArticleIdList></Reference><Reference><Citation>Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res. 2014;19(194):145&#x2013;158. doi: 10.1016/j.virusres.2014.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.09.011</ArticleId><ArticleId IdType="pmc">PMC7114389</ArticleId><ArticleId IdType="pubmed">25281913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Wang K, Yu J, Howard D, French L, Chen Z, Wen C, Xu Z. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol. 2021;20(11):1860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7855591</ArticleId><ArticleId IdType="pubmed">33551947</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia MA, Barreras PV, Lewis A, Pinilla G, Sokoll LJ, Kickler T, Mostafa H, Caturegli M, Moghekar A, Fitzgerald KC, Neuro-COVID H. Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm. J Neurol Sci. 2021;15(427):117517. doi: 10.1016/j.jns.2021.117517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117517</ArticleId><ArticleId IdType="pmc">PMC8166041</ArticleId><ArticleId IdType="pubmed">34090021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharraziha I, Axelsson J, Ricci F, DiMartino G, Persson M, Sutton R, Fedorowski A, Hamrefors V. Serumactivityagainstg protein&#x2013;coupled receptors and severity of orthostatic symptoms in postural orthostatic tachycardia syndrome. J Am Heart Assoc. 2020;9:e015989. doi: 10.1161/JAHA.120.015989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.015989</ArticleId><ArticleId IdType="pmc">PMC7792263</ArticleId><ArticleId IdType="pubmed">32750291</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovere-Querini P, De Lorenzo R, Conte C, Brioni E, Lanzani C, Yacoub MR, Chionna R, Martinenghi S, Vitali G, Tresoldi M, Ciceri F. Post-COVID-19 follow-up clinic: depicting chronicity of a new disease. Acta Bio Medica: Atenei Parmensis. 2020;91(9S):22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023087</ArticleId><ArticleId IdType="pubmed">32701913</ArticleId></ArticleIdList></Reference><Reference><Citation>Onohuean H, Al-Kuraishy HM, Al-Gareeb AI, Qusti S, Alshammari EM, Batiha GE. COVID-19 and development of heart failure: mystery and truth. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(10):2013&#x2013;2021. doi: 10.1007/s00210-021-02147-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-021-02147-6</ArticleId><ArticleId IdType="pmc">PMC8417660</ArticleId><ArticleId IdType="pubmed">34480616</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiq MM, Chan AT, Miorin L, Yadaw AS, Beaumont KG, Kehrer T, Cupic A, White KM, Tolentino RE, Hu B, Stern AD. Functional effects of cardiomyocyte injury in COVID-19. J Virol. 2021;13:603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8791272</ArticleId><ArticleId IdType="pubmed">34669512</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson FR, Jr, Bosukonda D, Keck PC, Carlson WD. Multiorgan damage in patients with COVID-19: is the TGF-&#x3b2;/BMP pathway the missing link? Basic Transl Sci. 2020;5(11):1145&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7508496</ArticleId><ArticleId IdType="pubmed">32984657</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai AD, Boursiquot BC, Melki L, Wan EY. Management of arrhythmias associated with COVID-19. Curr Cardiol Rep. 2020;23:2. doi: 10.1007/s11886-020-01434-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-020-01434-7</ArticleId><ArticleId IdType="pmc">PMC7685181</ArticleId><ArticleId IdType="pubmed">33231782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P, Calcaterra I, Molino A, Moretta P, Lupoli R, Spedicato GA, Papa A, Motta A, Maniscalco M, Di Minno MN. Persistent endothelial dysfunction in post-acute COVID-19 syndrome: a case-control study. Biomedicines. 2021;9(8):957. doi: 10.3390/biomedicines9080957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080957</ArticleId><ArticleId IdType="pmc">PMC8391623</ArticleId><ArticleId IdType="pubmed">34440161</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and infammatory cardiac channelopathies. Nat Rev Immunol. 2019;19:63&#x2013;64. doi: 10.1038/s41577-018-0098-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0098-z</ArticleId><ArticleId IdType="pubmed">30552387</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F, Vasa-Nicotera M, Zeiher AM, Vehreschild M. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5(11):1265&#x2013;1273. doi: 10.1001/jamacardio.2020.3557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.3557</ArticleId><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Moody WE, Liu B, Mahmoud-Elsayed HM, Senior J, Lalla SS, Khan-Kheil AM, Brown S, Saif A, Moss A, Bradlow WM, Khoo J. Persisting adverse ventricular remodeling in COVID-19 survivors: a longitudinal echocardiographic study. J Am Soc Echocardiogr. 2021;34(5):562&#x2013;566. doi: 10.1016/j.echo.2021.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2021.01.020</ArticleId><ArticleId IdType="pmc">PMC8008825</ArticleId><ArticleId IdType="pubmed">33539950</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, Daniels CJ. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2021;6(1):116&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489396</ArticleId><ArticleId IdType="pubmed">32915194</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasecka A, Pruc M, Kukula K, Gilis-Malinowska N, Filipiak KJ, Jaguszewski MJ, Szarpak L. Post-COVID-19 heart syndrome. Cardiol J. 2021;28(2):353&#x2013;354. doi: 10.5603/CJ.a2021.0028.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/CJ.a2021.0028</ArticleId><ArticleId IdType="pmc">PMC8078939</ArticleId><ArticleId IdType="pubmed">33645626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambadiari V, Mitrakou A, Kountouri A, Thymis J, Katogiannis K, Korakas E, Varlamos C, Andreadou I, Tsoumani M, Triantafyllidi H, Bamias A. Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. Eur J Heart Fail. 2021;23(11):1916&#x2013;1926. doi: 10.1002/ejhf.2326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2326</ArticleId><ArticleId IdType="pmc">PMC8426810</ArticleId><ArticleId IdType="pubmed">34415085</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpek M. Does COVID-19 cause hypertension? Angiology. 2021;10:00033197211053903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9260192</ArticleId><ArticleId IdType="pubmed">34889662</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi R, Coppi F, Monopoli DE, Sgura FA, Arrotti S, Boriani G. Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors. Cardiol J. 2021;29:163&#x2013;165. doi: 10.5603/CJ.a2021.0159.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/CJ.a2021.0159</ArticleId><ArticleId IdType="pmc">PMC8890407</ArticleId><ArticleId IdType="pubmed">34897638</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI. COVID-19 and acute kidney injury: a new perspective. Age (years) 2021;1(30):42.</Citation><ArticleIdList><ArticleId IdType="pubmed">35130242</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI. Acute kidney injury and COVID-19. Egypt J Internal Med. 2021;33(1):1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492093</ArticleId><ArticleId IdType="pubmed">34629845</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent J, Aklilu A, Yamamoto Y, Simonov M, Li F, Biswas A, Ghazi L, Greenberg JH, Mansour SG, Moledina DG, Wilson FP. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. JAMA Netw Open. 2021;4(3):e211095. doi: 10.1001/jamanetworkopen.2021.1095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.1095</ArticleId><ArticleId IdType="pmc">PMC7948062</ArticleId><ArticleId IdType="pubmed">33688965</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X, Huang L, Cui D, Wang Y, Wang Y, Xu J, Shang L, Fan G, Cao B. Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: a cohort study. EBioMedicine. 2022;1(76):103817. doi: 10.1016/j.ebiom.2022.103817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103817</ArticleId><ArticleId IdType="pmc">PMC8776508</ArticleId><ArticleId IdType="pubmed">35074630</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf F, Fahriani M, Mamada SS, Frediansyah A, Abubakar A, Maghfirah D, Fajar JK, Maliga HA, Ilmawan M, Emran TB, Ophinni Y. Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: a systematic review and meta-analysis. F1000Research. 2021;10:301. doi: 10.12688/f1000research.52216.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.52216.1</ArticleId><ArticleId IdType="pmc">PMC8171196</ArticleId><ArticleId IdType="pubmed">34131481</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;5. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathish T, Cao Y, Kapoor N. Newly diagnosed diabetes in COVID-19 patients. Prim Care Diabetes. 2021;15(1):194. doi: 10.1016/j.pcd.2020.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcd.2020.08.014</ArticleId><ArticleId IdType="pmc">PMC7451214</ArticleId><ArticleId IdType="pubmed">32900656</ArticleId></ArticleIdList></Reference><Reference><Citation>Chng CL, Tan HC, Too CW, Lim WY, Chiam PP, Zhu L, Nadkarni NV, Lim AY. Diagnostic performance of ATA, BTA and TIRADS sonographic patterns in the prediction of malignancy in histologically proven thyroid nodules. Singapore Med J. 2018;59(11):578. doi: 10.11622/smedj.2018062.</Citation><ArticleIdList><ArticleId IdType="doi">10.11622/smedj.2018062</ArticleId><ArticleId IdType="pmc">PMC6250759</ArticleId><ArticleId IdType="pubmed">29774361</ArticleId></ArticleIdList></Reference><Reference><Citation>Feghali K, Atallah J, Norman C. Manifestations of thyroid disease post COVID-19 illness: report of Hashimoto thyroiditis, Graves&#x2019; disease, and subacute thyroiditis. J Clin Transl Endocrinol Case Rep. 2021;1(22):100094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8387132</ArticleId><ArticleId IdType="pubmed">34462717</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Perez O, Merino E, Alfayate R, Torregrosa ME, Andres M, Leon-Ramirez JM, Boix V, Gil J, Pico A. COVID19-ALC Research group. Male pituitary&#x2013;gonadal axis dysfunction in post-acute COVID-19 syndrome&#x2014;prevalence and associated factors: a Mediterranean case series. Clin Endocrinol. 2021;96:353&#x2013;362. doi: 10.1111/cen.14537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen.14537</ArticleId><ArticleId IdType="pmc">PMC8444731</ArticleId><ArticleId IdType="pubmed">34160836</ArticleId></ArticleIdList></Reference><Reference><Citation>Urhan E, Karaca Z, Unuvar GK, Gundogan K, Unluhizarci K. Investigation of pituitary functions after acute coronavirus disease 2019. Endocr J. 2022;69:649&#x2013;658. doi: 10.1507/endocrj.EJ21-0531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.EJ21-0531</ArticleId><ArticleId IdType="pubmed">34987144</ArticleId></ArticleIdList></Reference><Reference><Citation>Talwar D, Madaan S, Kumar S, Jaiswal A, Khanna S, Hulkoti V, Eleti MR. Post COVID hypothalamic-pituitary-adrenal axis dysfunction manifesting as perinatal depression: a case series. Med Sci. 2021;25(112):1402&#x2013;1406.</Citation></Reference><Reference><Citation>Kothandaraman N, Rengaraj A, Xue B, Yew WS, Velan SS, Karnani N, Leow MK. COVID-19 endocrinopathy with hindsight from SARS. Am J Physiol Endocrinol Metab. 2021;320(1):E139&#x2013;E150. doi: 10.1152/ajpendo.00480.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00480.2020</ArticleId><ArticleId IdType="pmc">PMC7816429</ArticleId><ArticleId IdType="pubmed">33236920</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193&#x2013;199. doi: 10.1007/s00592-009-0109-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-009-0109-4</ArticleId><ArticleId IdType="pmc">PMC7088164</ArticleId><ArticleId IdType="pubmed">19333547</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Misra A. Post COVID-19 syndrome (&#x201c;Long COVID&#x201d;) and diabetes: challenges in diagnosis and management. Diabetes Metab Syndr. 2021;15(5):102235. doi: 10.1016/j.dsx.2021.102235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102235</ArticleId><ArticleId IdType="pmc">PMC8317446</ArticleId><ArticleId IdType="pubmed">34384972</ArticleId></ArticleIdList></Reference><Reference><Citation>Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, Bauer KA, Zwicker JI. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136(11):1342&#x2013;1346. doi: 10.1182/blood.2020007938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007938</ArticleId><ArticleId IdType="pmc">PMC7483433</ArticleId><ArticleId IdType="pubmed">32766883</ArticleId></ArticleIdList></Reference><Reference><Citation>Salisbury R, Iotchkova V, Jaafar S, Morton J, Sangha G, Shah A, Untiveros P, Curry N, Shapiro S. Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Adv. 2020;4(24):6230&#x2013;6239. doi: 10.1182/bloodadvances.2020003349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003349</ArticleId><ArticleId IdType="pmc">PMC7757009</ArticleId><ArticleId IdType="pubmed">33351117</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudhabhay I, Rabant M, Roumenina LT, Coupry LM, Poillerat V, Marchal A, Fr&#xe9;meaux-Bacchi V, El Karoui K, Monchi M, Pourcine F. Case report: adult post-COVID-19 multisystem inflammatory syndrome and thrombotic microangiopathy. Front Immunol. 2021;23(12):2284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260674</ArticleId><ArticleId IdType="pubmed">34248962</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581&#x2013;589. doi: 10.1038/s41584-020-0474-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0474-5</ArticleId><ArticleId IdType="pmc">PMC7391481</ArticleId><ArticleId IdType="pubmed">32733003</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Anderson D, Rathore AP, O'Neill A, Mantri CK, Saron WA, Lee C, Chu WC, Kang A, Foo R, Kalimuddin S. Signatures of mast cell activation are associated with severe COVID-19. medRxiv. 2021;586:509.</Citation></Reference><Reference><Citation>Molderings GJ, Kolck UW, Scheurlen C, Br&#xfc;ss M, Homann J, Von K&#xfc;gelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol. 2007;42(9):1045&#x2013;1053. doi: 10.1080/00365520701245744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365520701245744</ArticleId><ArticleId IdType="pubmed">17710669</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell AJ, Ding J, You Y, Dong Z, Chehade H, Alvero A, Mor Y, Draghici S, Mor G. Identification of key signaling pathways induced by SARS-CoV2 that underlie thrombosis and vascular injury in COVID-19 patients. J Leukoc Biol. 2021;109(1):35&#x2013;47. doi: 10.1002/JLB.4COVR0920-552RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.4COVR0920-552RR</ArticleId><ArticleId IdType="pmc">PMC7753679</ArticleId><ArticleId IdType="pubmed">33242368</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee R, Bhattacharya A, Bojkova D, Mehdipour AR, Shin D, Khan KS, Cheung HH, Wong KB, Ng WL, Cinatl J, Geurink PP. Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. J Biol Chem. 2021;297(2):100925. doi: 10.1016/j.jbc.2021.100925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100925</ArticleId><ArticleId IdType="pmc">PMC8241579</ArticleId><ArticleId IdType="pubmed">34214498</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors (Oxford, England) 2020;46:306. doi: 10.1002/biof.1633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1633</ArticleId><ArticleId IdType="pmc">PMC7267424</ArticleId><ArticleId IdType="pubmed">32339387</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerappan A, Reid AC, Estephan R, et al. Mast cell renin and a local renin-angiotensin system in the airway: role in bronchoconstriction. Proc Natl Acad Sci USA. 2008;105(4):1315&#x2013;1320. doi: 10.1073/pnas.0709739105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0709739105</ArticleId><ArticleId IdType="pmc">PMC2234135</ArticleId><ArticleId IdType="pubmed">18202178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs B, Sj&#xf6;berg L, Westerberg CM, Ekoff M, Swedin L, Dahl&#xe9;n SE, Adner M, Nilsson GP. Mast cell engraftment of the peripheral lung enhances airway hyperresponsiveness in a mouse asthma model. Am J Physiol Lung Cell Mol Physiol. 2012;303(12):L1027&#x2013;L1036. doi: 10.1152/ajplung.00227.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00227.2012</ArticleId><ArticleId IdType="pubmed">23043076</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519(7542):237&#x2013;241. doi: 10.1038/nature14022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14022</ArticleId><ArticleId IdType="pmc">PMC4359082</ArticleId><ArticleId IdType="pubmed">25517090</ArticleId></ArticleIdList></Reference><Reference><Citation>Komi DE, Khomtchouk K, Santa Maria PL. A review of the contribution of mast cells in wound healing: involved molecular and cellular mechanisms. Clin Rev Allergy Immunol. 2020;58(3):298&#x2013;312. doi: 10.1007/s12016-019-08729-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-019-08729-w</ArticleId><ArticleId IdType="pubmed">30729428</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehboob R, Lavezzi AM. Neuropathological explanation of minimal COVID-19 infection rate in newborns, infants and children&#x2013;a mystery so far. New insight into the role of Substance P. J Neurol Sci. 2021;420:117276. doi: 10.1016/j.jns.2020.117276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117276</ArticleId><ArticleId IdType="pmc">PMC7834711</ArticleId><ArticleId IdType="pubmed">33360484</ArticleId></ArticleIdList></Reference><Reference><Citation>Karamyan VT. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19? Physiol Rep. 2021;9(5):e14796. doi: 10.14814/phy2.14796.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14796</ArticleId><ArticleId IdType="pmc">PMC7941673</ArticleId><ArticleId IdType="pubmed">33687143</ArticleId></ArticleIdList></Reference><Reference><Citation>Caillet-Saguy C, Durbesson F, Rezelj VV, Gogl G, Tran QD, Twizere JC, Vignuzzi M, Vincentelli R, Wolff N. Host PDZ-containing proteins targeted by SARS-CoV-2. FEBS J. 2021;288(17):5148&#x2013;5162. doi: 10.1111/febs.15881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15881</ArticleId><ArticleId IdType="pmc">PMC8250131</ArticleId><ArticleId IdType="pubmed">33864728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler JB, Butuci M, Wong A, Kamboj AP, Youngblood BA. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy. 2022;77(4):1288. doi: 10.1111/all.15188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15188</ArticleId><ArticleId IdType="pmc">PMC9299596</ArticleId><ArticleId IdType="pubmed">34820848</ArticleId></ArticleIdList></Reference><Reference><Citation>Szukiewicz D, Wojdasiewicz P, Watroba M, Szewczyk G. Mast cell activation syndrome in COVID-19 and female reproductive function: theoretical background vs. accumulating clinical evidence. J Immunol Res. 2022;2022:1&#x2013;22. doi: 10.1155/2022/9534163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/9534163</ArticleId><ArticleId IdType="pmc">PMC9242765</ArticleId><ArticleId IdType="pubmed">35785029</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: luteolin to the rescue. BioFactors. 2021;47(2):232&#x2013;241. doi: 10.1002/biof.1726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1726</ArticleId><ArticleId IdType="pmc">PMC8250989</ArticleId><ArticleId IdType="pubmed">33847020</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan K, Lin Y, Prewitt KR, Potter DA. Multidisciplinary approach to brain fog and related persisting symptoms post COVID-19. J Health Serv Psychol. 2022;2:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809226</ArticleId><ArticleId IdType="pubmed">35128461</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, Guo L, Yang J, Wang C, Jiang S, Yang D. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27(6):883&#x2013;890. doi: 10.1016/j.chom.2020.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7196896</ArticleId><ArticleId IdType="pubmed">32407669</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis. 2021;1(112):217&#x2013;226. doi: 10.1016/j.ijid.2021.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD. COVID-19: famotidine, histamine, mast cells, and mechanisms. Front Pharmacol. 2021;23(12):216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8021898</ArticleId><ArticleId IdType="pubmed">33833683</ArticleId></ArticleIdList></Reference><Reference><Citation>Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, Church MK, Saluja R. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol. 2018;13(9):1873. doi: 10.3389/fimmu.2018.01873.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01873</ArticleId><ArticleId IdType="pmc">PMC6099187</ArticleId><ArticleId IdType="pubmed">30150993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HD, Van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther. 2005;314:1310&#x2013;1321. doi: 10.1124/jpet.105.087965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.105.087965</ArticleId><ArticleId IdType="pubmed">15947036</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurmond RL. The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015;6:65. doi: 10.3389/fphar.2015.00065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2015.00065</ArticleId><ArticleId IdType="pmc">PMC4379874</ArticleId><ArticleId IdType="pubmed">25873897</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurmond RL, Chen B, Dunford PJ, Greenspan AJ, Karlsson L, La D, et al. Clinical and preclinical characterization of the histamine H(4) receptor antagonist JNJ-39758979. J Pharmacol Exp Ther. 2014;349:176&#x2013;184. doi: 10.1124/jpet.113.211714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.113.211714</ArticleId><ArticleId IdType="pubmed">24549371</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med. 2022;70(1):61&#x2013;67. doi: 10.1136/jim-2021-002051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama I. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve Post-COVID syndrome? Drug Discov Ther. 2020;14(5):259&#x2013;261. doi: 10.5582/ddt.2020.03095.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/ddt.2020.03095</ArticleId><ArticleId IdType="pubmed">33116043</ArticleId></ArticleIdList></Reference><Reference><Citation>Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, Panse J, Butterfield J, Afrin LB. Pharmacological treatment options for mast cell activation disease. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(7):671&#x2013;694. doi: 10.1007/s00210-016-1247-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-016-1247-1</ArticleId><ArticleId IdType="pmc">PMC4903110</ArticleId><ArticleId IdType="pubmed">27132234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaakati R, Khokhar D, Akin C. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract. 2021;9(8):3198&#x2013;9. doi: 10.1016/j.jaip.2021.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8141687</ArticleId><ArticleId IdType="pubmed">34033981</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwensen HF, Borreschmidt LK, Storgaard M, Redsted S, Christensen S, Madsen LB. Fatal pulmonary fibrosis: a post-COVID-19 autopsy case. J Clin Pathol. 2021;74(6):400&#x2013;402. doi: 10.1136/jclinpath-2020-206879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2020-206879</ArticleId><ArticleId IdType="pubmed">32723800</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SH, Kim JY, Kim JM, Yoo BR, Han SY, Jung YJ, Bae H, Cho J. PM014 attenuates radiation-induced pulmonary fibrosis via regulating NF-kB and TGF-b1/NOX4 pathways. Sci Rep. 2020;10(1):1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7527517</ArticleId><ArticleId IdType="pubmed">32999298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2. Eur J Clin Pharmacol. 2020;76(11):1615&#x2013;1618. doi: 10.1007/s00228-020-02947-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-020-02947-4</ArticleId><ArticleId IdType="pmc">PMC7320911</ArticleId><ArticleId IdType="pubmed">32594204</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zhigang Z, Ting L. Post-inflammatory pulmonary fibrosis in a discharged COVID-19 patient: Effectively treated with Pirfenidone. Arch Pulmonol Respir Care. 2020;6(1):051&#x2013;53.</Citation></Reference><Reference><Citation>Ryan J, Fernando J, Barnstein B. TGFb1 suppresses the mast cell response in vitro and in vivo. J Immunol. 2010;184(1):86.6.</Citation></Reference><Reference><Citation>Folkerts J, Redegeld F, Folkerts G, Blokhuis B, van den Berg MP, de Bruijn MJ, van Ijcken WF, Junt T, Tam SY, Galli SJ, Hendriks RW. Butyrate inhibits human mast cell activation via epigenetic regulation of Fc&#x3b5;RI-mediated signaling. Allergy. 2020;75(8):1966&#x2013;78. doi: 10.1111/all.14254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14254</ArticleId><ArticleId IdType="pmc">PMC7703657</ArticleId><ArticleId IdType="pubmed">32112426</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanin J, Gebremeskel S, Korver W, Falahati R, Butuci M, Haw TJ, Nair PM, Liu G, Hansbro NG, Hansbro PM, Evensen E. A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation. Mucosal Immunol. 2021;14(2):366&#x2013;376. doi: 10.1038/s41385-020-00336-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-020-00336-9</ArticleId><ArticleId IdType="pmc">PMC7946634</ArticleId><ArticleId IdType="pubmed">32814824</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermans MA, Schrijver B, van Holten-Neelen CC, van Wijk RG, van Hagen PM, van Daele PL, Dik WA. The JAK1/JAK2-inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy. 2018;48(11):1412&#x2013;20. doi: 10.1111/cea.13217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.13217</ArticleId><ArticleId IdType="pubmed">29939445</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>